Prognostic significance of hepatic encephalopathy in patients with cirrhosis treated with current standards of care

被引:0
作者
Anuj Bohra [1 ]
Thomas Worland [1 ,2 ]
Samuel Hui [1 ]
Ryma Terbah [2 ]
Ann Farrell [1 ]
Marcus Robertson [1 ,2 ,3 ]
机构
[1] Department of Gastroenterology,Monash Health  2. Department of Gastroenterology,Austin Health
[2] Department of Medicine,School of Clinical Sciences,Monash University
关键词
Hepatic encephalopathy; Cirrhosis; Portal hypertension; Prognosis; Rifaximin; Lactulose;
D O I
暂无
中图分类号
R473.5 [内科护理学];
学科分类号
1011 ;
摘要
BACKGROUND Hepatic encephalopathy(HE) is a reversible neuropsychiatric complication of liver cirrhosis and occurs in up to 50% of cirrhotic patients. Studies examining the prognostic significance of HE are limited despite the high prevalence in cirrhosis.AIM To define the clinical outcomes of patients after an episode of HE treated with current standards-of-care.METHODS All patients hospitalised with HE requiring Rifaximin to 3 tertiary centres over46-mo(2012–2016) were identified via pharmacy dispensing records. Patients with hepatocellular carcinoma and those prescribed Rifaximin prior to admission were excluded. Medical records were reviewed to determine baseline characteristics and survival. The Kaplan-Meier method was used to calculate survival probability. Univariate survival analysis was performed with variables reaching statistical significance included in a multivariate analysis. The primary outcome was 12-mo mortality following commencement of Rifaximin.RESULTS188 patients were included. Median age was 57 years(IQR 50-65), 71% were male and median model for end stage liver disease and Child Pugh scores were 25(IQR 18-31) and 11(IQR 9-12) respectively. The most common causes of cirrhosis were alcohol(62%), hepatitis C(31%) and non-alcoholic fatty liver disease(20%).A precipitating cause for HE was found in 92% patients with infection(43%), GI bleeding(16%), medication non-compliance(15%) and electrolyte imbalance(14%) the most common. During a mean follow up period of 12 ± 13 mo 107(57%) patients died and 32(17%) received orthotopic liver transplantation. Themost common causes of death were decompensated chronic liver disease(57%)and sepsis(19%). The probability of survival was 44% and 35% at 12-and 24-mo respectively. At multivariate analysis a model for end stage liver disease > 15 and international normalised ratio reached statistical significance in predicting mortality.CONCLUSION Despite advances made in the management of HE patients continue to have poor survival. Thus, in all patients presenting with HE the appropriateness of orthotopic liver transplantation should be considered.
引用
收藏
页码:2221 / 2231
页数:11
相关论文
共 50 条
  • [21] Prognostic significance and economic burden of hepatic encephalopathy in liver cirrhosis in German hospitals based on G-DRG data
    Gundling, Felix
    Rathmayer, Markus
    Koller, Lisa
    Wilke, Michael
    Kircheis, Gerald
    Wedemeyer, Heiner
    Labenz, Joachim
    Albert, Joerg
    Schepp, Wolfgang
    Lerch, Markus M.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2020, 58 (04): : 323 - 331
  • [22] Hepatic Encephalopathy: Early Diagnosis in Pediatric Patients With Cirrhosis
    Dara, Naghi
    Sayyari, Ali-Akbar
    Imanzadeh, Farid
    IRANIAN JOURNAL OF CHILD NEUROLOGY, 2014, 8 (01) : 1 - 11
  • [23] Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door
    Catherine T. Frenette
    Cynthia Levy
    Sammy Saab
    Digestive Diseases and Sciences, 2022, 67 : 1994 - 2004
  • [24] Hepatic Encephalopathy-Related Hospitalizations in Cirrhosis: Transition of Care and Closing the Revolving Door
    Frenette, Catherine T.
    Levy, Cynthia
    Saab, Sammy
    DIGESTIVE DISEASES AND SCIENCES, 2022, 67 (06) : 1994 - 2004
  • [25] FACTORS LEADING TO HEPATIC ENCEPHALOPATHY IN PATIENTS WITH LIVER CIRRHOSIS AT A TERTIARY CARE HOSPITAL IN KARACHI, PAKISTAN
    Achakzai, Muhammad Sadiq
    Shaikh, Hafeezullah
    Mobin, Ahsan
    Majid, Shahid
    Javed, Anjum
    Bin Khalid, Abdullah
    Usmani, Muhammad Tayyab
    Shaikh, Ubedullah
    GOMAL JOURNAL OF MEDICAL SCIENCES, 2016, 14 (02): : 71 - 74
  • [26] Impact of rifaximin use in infections and mortality in patients with decompensated cirrhosis and hepatic encephalopathy
    Idalsoaga, Francisco
    Robles, Camila
    Ortiz, Andrea
    Corsi, Oscar
    Fuentes-Lopez, Eduardo
    Diaz, Luis Antonio
    Ayares, Gustavo
    Arrese, Marco
    Arab, Juan Pablo
    THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2024, 17
  • [27] Electroencephalography Signatures for Hepatic Encephalopathy in Cirrhosis Patients Treated with Proton Pump Inhibitors: An Exploratory Pilot Study
    Zhang, Pan
    Zhou, Lizhi
    Chen, Li
    Zhang, Zhen
    Han, Rui
    Guo, Gangwen
    Zhou, Haocheng
    BIOMEDICINES, 2022, 10 (12)
  • [28] Current vision on diagnosis and comprehensive care in hepatic encephalopathy
    Higuera-de-la-Tijera, F.
    Velasco, J. A. Velarde-Ruiz
    Rana-Garibay, R. H.
    Castro-Narro, G. E.
    Abdo-Francis, J. M.
    Moreno-Alcantar, R.
    Perez-Hernandez, J. L.
    Torre, A.
    Contreras-Omana, R.
    Cano-Contreras, A.
    Castillo-Barradas, M.
    Perez-Escobar, J.
    Aldana-Ledesma, J. M.
    Cerda-Reyes, E.
    Fernandez-Perez, N. J.
    Meza-Cardona, J.
    Flores-Garcia, N. C.
    Reyes-Bastidas, M.
    Lira-Verao, J. E.
    Garcia-Jimenez, E. S.
    Santana-Vargas, D.
    Paez-Zayasa, V. M.
    Chavez-Tapia, N. C.
    Marquez-Guillen, E.
    REVISTA DE GASTROENTEROLOGIA DE MEXICO, 2023, 88 (02): : 155 - 174
  • [29] Factors associated with nonresponse to lactulose in patients with cirrhosis and hepatic encephalopathy
    Qureshi, Muhammad Omar
    Shafqat, Farzana
    Salih, Mohammad
    Khokhar, Nasir
    RAWAL MEDICAL JOURNAL, 2014, 39 (02): : 115 - 118
  • [30] Is acarbose an effective drug for treating patients with cirrhosis and hepatic encephalopathy?
    Mullen, KD
    Howard, R
    NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY, 2005, 2 (06): : 264 - 265